Umbralisib, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib is a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon. Umbralisib was granted accelerated approval for medical use in the United States in February 2021.<\/p>\n
The most common side effects include increased creatinine, diarrhea-colitis, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash.<\/p>\n
To access umbralisib tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Ukoniq (umbralisib tablets) for oral use Initial U.S. Approval: 2021<\/p>\n","protected":false},"excerpt":{"rendered":"
Ukoniq (umbralisib) is a medication used for the treatment of adult patients with subtypes of Non-Hodgkin Lymphoma, namely relapsed or refractory marginal zone lymphoma (MZL) and relapsed or refractory follicular lymphoma (FL).<\/p>\n
DISEASE INDICATIONS-Lymphoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cumbralisib tablets\u201d based on the information you provide.<\/p>\n
\nMANUFACTURER-TG Therapeutics
\nUSAGE-Oral
\nMEDICINE APPROVED BY-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n